-+ 0.00%
-+ 0.00%
-+ 0.00%

Guggenheim Reiterates Buy on InflaRx, Maintains $14 Price Target

Benzinga·04/21/2026 13:39:08
Listen to the news
Guggenheim analyst Yatin Suneja reiterates InflaRx (NASDAQ:IFRX) with a Buy and maintains $14 price target.